OSE IMMUNO news, videos and press releases
For more news please use our advanced search feature.
OSE IMMUNO - More news...
OSE IMMUNO - More news...
- OSE Immunotherapeutics Receives €8.4 M in Public Funding to Support the Registration Phase 3 Clinical Trial of Cancer Vaccine Tedopi® in Lung Cancer
- AbbVie and OSE Immunotherapeutics Announce Partnership to Develop a Novel Monoclonal Antibody for the Treatment of Chronic Inflammation
- OSE Immunotherapeutics Announces New Public Grant to Support Innovation and Research Programs in the Field of RNA Therapeutics
- OSE Immunotherapeutics Announces Publication in Frontiers in Immunology on OSE-230, its Novel Agonist Therapy in Chronic Inflammation
- OSE Immunotherapeutics and Nantes University Hospital Announce Completion of Patient Enrollment in the FIRsT Clinical Trial, a Phase 1/2 Study Evaluating FR104/VEL-101 Immunotherapy in Renal Transplantation
- OSE Immunotherapeutics Announces for Lusvertikimab, its Anti-IL-7 Receptor Antagonist:
- OSE Immunotherapeutics Announces New US Patent Granted for the Use of Tedopi® in Cancer Patients after Failure with PD-1/PD-L1 Immune Checkpoint Inhibitor Treatment
- OSE Immunotherapeutics Reports on its 2023 Combined General Shareholder’s Meeting
- OSE Immunotherapeutics Receives €1.5 M in Funding from Bpifrance for the Development of a Companion Diagnostic for the Cancer Vaccine Tedopi® in Non-Small Cell Lung Cancer
- OSE Immunotherapeutics Presents Update on BiCKI®IL-7, CLEC-1 and OSE-230 Preclinical Programs in Immuno-Oncology and Immuno-Inflammation At International Conferences
- OSE Immunotherapeutics Presents Clinical Abstracts on Tedopi® at the ASCO 2023 Annual Meeting
- OSE Immunotherapeutics’ Board of Directors Proposes the Appointment of Eric Leire, MD, as New Independent Director
- OSE Immunotherapeutics (OSE): Re-initiation – Milestones anticipated throughout FY23
- OSE Immunotherapeutics and GERCOR Oncology Clinician Group Announce Completion of Patient Enrollment in TEDOPaM Phase 2 Clinical Trial with Tedopi® in Advanced Pancreatic Cancer (GERCOR D17-01 PRODIGE 63 trial)
- OSE Immunotherapeutics to Continue the Clinical Development in Ulcerative Colitis with Full Rights to Lusvertikimab
- OSE Immunotherapeutics Reports Full Year 2022 Financial Results and Provides Business Strategy Update
- OSE Immunotherapeutics Presents Additional Preclinical Updates on CLEC-1, a Novel Myeloid Immune Checkpoint in Immuno-Oncology
- OSE Immunotherapeutics Presents Clinical and Preclinical Data from its Immuno-Oncology Portfolio
- OSE Immunotherapeutics to Present Preclinical and Clinical Research Updates from its Pipeline and Platforms in Immuno-Oncology
- OSE Immunotherapeutics Receives New Approval for an Early Access Program for Tedopi® in Spain in Non-Small Cell Lung Cancer After Failure to Immunotherapies
- OSE Immunotherapeutics Updates on Anti-IL-7 Receptor Antagonist OSE-127/S95011, a Breakthrough Approach in Chronic Inflammatory Autoimmune Diseases and Hematology
- OSE Immunotherapeutics Provides Regulatory Update on Tedopi®, a Cancer Vaccine at a Late-Stage Clinical Development in Lung Cancer After Failure to Immunotherapies
- OSE Immunotherapeutics Announces Upcoming Investor Meetings in Q1 2023
- OSE Immunotherapeutics Announces First Patient Dosed with Anti-PD1 Monoclonal Antibody OSE-279 in a Phase 1/2 Clinical Trial in Advanced Solid Tumors or Lymphomas
- OSE Immunotherapeutics Receives a €10 Million Payment Corresponding to the Second Tranche of the Financing Granted by the European Investment Bank
- OSE Immunotherapeutics Announces Latest Preclinical Efficacy Data on its Anti-IL-7 Receptor Antagonist OSE-127 in Acute Lymphoblastic Leukemia at the 2022 American Society of Hematology (ASH) Annual Meeting
- OSE Immunotherapeutics Announces Publication of Peer-Reviewed Data on CLEC-1, its Novel Myeloid Immune Checkpoint in ‘Science Advances’
- OSE Immunotherapeutics Builds a Strong R&D Strategy Through Innovative First-in-Class Multi-Platform Programs
- OSE Immunotherapeutics Announces Award for OSE-127's Upcoming Oral Presentation in Acute Lymphoblastic Leukemia
- Servier and OSE Immunotherapeutics Announce Completion of Patient Enrollment in the Phase 2a Clinical Trial of OSE-127/S95011 in Primary Sjögren’s Syndrome
